PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
81.18%
ROE of 81.18% versus zero median in Healthcare. Walter Schloss would verify if slight profitability advantage matters long-term.
22.76%
ROA of 22.76% while Healthcare median is zero. Peter Lynch would see if minimal profitability can widen over time.
-102.19%
Negative ROCE while Healthcare median is 0.00%. Seth Klarman would investigate whether a turnaround is viable.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.